Show simple item record

dc.contributor.authorSoda, Narshone
dc.contributor.authorRehm, Bernd HA
dc.contributor.authorSonar, Prashant
dc.contributor.authorNam-Trung, Nguyen
dc.contributor.authorShiddiky, Muhammad JA
dc.date.accessioned2020-01-23T23:14:19Z
dc.date.available2020-01-23T23:14:19Z
dc.date.issued2019
dc.identifier.issn2050-750X
dc.identifier.doi10.1039/c9tb01490j
dc.identifier.urihttp://hdl.handle.net/10072/390820
dc.description.abstractLiquid biopsy is a new diagnostic concept that provides important information for monitoring and identifying tumor genomes in body fluid samples. Detection of tumor origin biomolecules like circulating tumor cells (CTCs), circulating tumor specific nucleic acids (circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), microRNAs (miRNAs), long non-coding RNAs (lnRNAs)), exosomes, autoantibodies in blood, saliva, stool, urine, etc. enables cancer screening, early stage diagnosis and evaluation of therapy response through minimally invasive means. From reliance on painful and hazardous tissue biopsies or imaging depending on sophisticated equipment, cancer management schemes are witnessing a rapid evolution towards minimally invasive yet highly sensitive liquid biopsy-based tools. Clinical application of liquid biopsy is already paving the way for precision theranostics and personalized medicine. This is achieved especially by enabling repeated sampling, which in turn provides a more comprehensive molecular profile of tumors. On the other hand, integration with novel miniaturized platforms, engineered nanomaterials, as well as electrochemical detection has led to the development of low-cost and simple platforms suited for point-of-care applications. Herein, we provide a comprehensive overview of the biogenesis, significance and potential role of four widely known biomarkers (CTCs, ctDNA, miRNA and exosomes) in cancer diagnostics and therapeutics. Furthermore, we provide a detailed discussion of the inherent biological and technical challenges associated with currently available methods and the possible pathways to overcome these challenges. The recent advances in the application of a wide range of nanomaterials in detecting these biomarkers are also highlighted.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherRoyal Society of Chemistry
dc.relation.ispartofpagefrom6670
dc.relation.ispartofpageto6704
dc.relation.ispartofissue43
dc.relation.ispartofjournalJournal of Materials Chemistry B
dc.relation.ispartofvolume7
dc.subject.fieldofresearchMacromolecular and Materials Chemistry
dc.subject.fieldofresearchBiomedical Engineering
dc.subject.fieldofresearchcode0303
dc.subject.fieldofresearchcode0903
dc.subject.keywordsScience & Technology
dc.subject.keywordsTechnology
dc.subject.keywordsMaterials Science, Biomaterials
dc.subject.keywordsMaterials Science
dc.subject.keywordsCELL-FREE DNA
dc.titleAdvanced liquid biopsy technologies for circulating biomarker detection
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSoda, N; Rehm, BHA; Sonar, P; Nam-Trung, N; Shiddiky, MJA, Advanced liquid biopsy technologies for circulating biomarker detection, Journal of Materials Chemistry B, 2019, 7 (43), pp. 6670-6704
dc.date.updated2020-01-23T23:08:43Z
gro.hasfulltextNo Full Text
gro.griffith.authorShiddiky, Muhammad J.
gro.griffith.authorSonar, Prashant
gro.griffith.authorRehm, Bernd
gro.griffith.authorSoda, Narshone
gro.griffith.authorNguyen, Nam-Trung


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record